Recro Pharma, Inc. Contracts & Agreements

FIFTH AMENDMENT TO PURCHASE AND SALE AGREEMENT AND JOINT ESCROW INSTRUCTIONS (Filed With SEC on November 28, 2023)

First Amendment to Purchase and Sale Agreement and Joint Escrow Instructions, dated November 22, 2022, by and among Societal CDMO Gainesville, LLC, a Massachusetts limited... (Filed With SEC on November 8, 2023)

Second Amendment to Purchase and Sale Agreement and Joint Escrow Instructions, dated January 23, 2023, by and among Societal CDMO Gainesville, LLC, a Massachusetts limited... (Filed With SEC on November 8, 2023)

Third Amendment to Purchase and Sale Agreement and Joint Escrow Instructions, dated April 21, 2023, by and among Societal CDMO Gainesville, LLC, a Massachusetts limited liability... (Filed With SEC on November 8, 2023)

Fourth Amendment to Purchase and Sale Agreement and Joint Escrow Instructions, dated October 3, 2023, by and among Societal CDMO Gainesville, LLC, a Massachusetts limited... (Filed With SEC on November 8, 2023)

Underwriting Agreement, dated as of August 24, 2023, by and between Societal CDMO, Inc. and Craig-Hallum Capital Group, LLC, as representative of the underwriters (Filed With SEC on August 28, 2023)

Form of Pre-Funded Warrant (Filed With SEC on August 28, 2023)

Common Stock Purchase Warrant in favor of Warberg WF XI LP (as assigned by OTA LLC) (Filed With SEC on August 14, 2023)

Common Stock Purchase Warrant in favor of IriSys, Inc (Filed With SEC on August 14, 2023)

First Amendment to Subordinated Promissory Note (Filed With SEC on August 14, 2023)

Underwriting Agreement relating to the Common Offering, dated as of December 12, 2022, by and between Societal CDMO, Inc. and RBC Capital Markets, LLC, as representative of the... (Filed With SEC on December 13, 2022)

Underwriting Agreement relating to the Preferred Offering, dated as of December 12, 2022, by and between Societal CDMO, Inc. and RBC Capital Markets, LLC, as representative of the... (Filed With SEC on December 13, 2022)

Purchase and Sale Agreement, dated as of December 9, 2022, by and between Societal CDMO Gainesville, LLC and Tenet Equity Funding SPE Gainesville, LLC (Filed With SEC on December 12, 2022)

Form of Lease Agreement to be entered into by and between Societal CDMO Gainesville, LLC and Tenet Equity Funding SPE Gainesville, LLC (Filed With SEC on December 12, 2022)

Seventh Amendment to Credit Agreement, dated as of December 9, 2022, by and among Societal CDMO, Inc., certain subsidiaries of Societal CDMO, Inc., named as guarantors therein,... (Filed With SEC on December 12, 2022)

Credit Agreement, dated as of December 12, 2022, by Societal CDMO, Inc. in favor of RBC Capital Markets, LLC (Filed With SEC on December 12, 2022)

Purchase and Sale Agreement and Joint Escrow Instructions dated August 11, 2022, by and among Societal CDMO Gainesville, LLC, a Massachusetts limited liability company and Weekley... (Filed With SEC on August 16, 2022)

Amendment No. 3 to License and Supply Agreement, dated as of July 1, 2022 by and among Societal CDMO Gainesville LLC and Lannett Company, Inc (Filed With SEC on August 10, 2022)

Description of Securities (Filed With SEC on March 1, 2022)

Unit Purchase Agreement, dated August 13, 2021, by and among Recro Pharma, Inc., IriSys, LLC, the Sellers (as defined therein), and IriSys, Inc. as the Sellers Representative (Filed With SEC on August 13, 2021)

Form of Subordinated Promissory Note (Filed With SEC on August 13, 2021)

Sixth Amendment to Credit Agreement, dated as of August 13, 2021, by and among Recro Pharma, Inc., certain subsidiaries of Recro Pharma, Inc., named as guarantors therein, the... (Filed With SEC on August 13, 2021)

Form of Non-Qualified Stock Option Inducement Award Agreement (Filed With SEC on August 9, 2021)

Form of Inducement Award Agreement for Restricted Stock Units (Filed With SEC on August 9, 2021)

Underwriting Agreement, dated as of May 12, 2021, by and between Recro Pharma, Inc. and William Blair & Company, L.L.C., as representative of the underwriters (Filed With SEC on May 13, 2021)

Form of Non-Qualified Stock Option Award Agreement (Filed With SEC on February 26, 2021)

Form of Award Agreement for Restricted Stock Units (Filed With SEC on February 26, 2021)

Form of Award Agreement for Restricted Stock Units (performance-based) (Filed With SEC on February 26, 2021)

Second Amendment to Common Stock Purchase Agreement, by and between Aspire Capital Fund, LLC and Recro Pharma, Inc., dated February 26, 2021 (Filed With SEC on February 26, 2021)

Fifth Amendment to Credit Agreement and Investment Documents, dated as of February 19, 2021, by and between Recro Pharma, Inc. and Athyrium Opportunities III Acquisition LP (Filed With SEC on February 23, 2021)

Stock Issuance Agreement, dated as of February 19, 2021 by and between Recro Pharma, Inc., Athyrium Opportunities II Acquisition LP and Athyrium Opportunities III Acquisition LP (Filed With SEC on February 23, 2021)

Employment Agreement between Recro Pharma, Inc. and David Enloe, dated December 15, 2020 (Filed With SEC on December 21, 2020)

Employment Agreement between Recro Pharma, Inc. and Ryan Lake, dated December 15, 2020 (Filed With SEC on December 21, 2020)

Fourth Amendment to Credit Agreement and Investment Documents, dated as of November 5, 2020, by and between Recro Pharma, Inc. and Athyrium Opportunities III Acquisition LP (Filed With SEC on November 9, 2020)

Amendment No. 2 to License and Supply Agreement, dated as of November 5, 2020 by and among Recro Gainesville LLC, Kremers Urban Pharmaceuticals, Inc. and Lannett Company, Inc (Filed With SEC on November 9, 2020)

First Amendment to Common Stock Purchase Agreement, by and between Aspire Capital Fund, LLC and Recro Pharma, Inc., dated August 7, 2020 (Filed With SEC on August 10, 2020)

Note dated May 12, 2020, between Recro Pharma, Inc. and PNC Bank, National Association (Filed With SEC on May 15, 2020)

Description of Securities (Filed With SEC on March 4, 2020)

Employee Matters Agreement, dated February 12, 2020, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on March 4, 2020)

License and Supply Agreement, dated as of January 1, 2014, by and between Alkermes Pharma Ireland Limited and Kremers Urban Pharmaceuticals, Inc (Filed With SEC on March 4, 2020)

Amendment No. 1 to License and Supply Agreement, dated as of September 6, 2018, by and between Recro Gainesville LLC and Kremers Urban Pharmaceuticals, Inc (Filed With SEC on March 4, 2020)

Separation Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)

Tax Matters Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)

Employee Matters Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)

Transition Services Agreement, dated as of November 20, 2019, by and between Recro Pharma, Inc. and Baudax Bio, Inc (Filed With SEC on November 26, 2019)

Partial Assignment, Assumption and Bifurcation Agreement, dated November 20, 2019, by and among Alkermes Pharma Ireland Limited, Recro Gainesville LLC, Recro Pharma, Inc. and... (Filed With SEC on November 26, 2019)

Third Amendment to Credit Agreement and Release Agreement, dated as of October 22, 2019, by and between Recro Pharma, Inc. and Athyrium Opportunities III Acquisition LP (Filed With SEC on November 8, 2019)

Separation and Mutual Release Agreement, dated as of May 14, 2019, by and between Recro Pharma, Inc. and Michael Celano (Filed With SEC on May 15, 2019)

Supplemental Agreement No. 3 to the Amended and Restated License and Supply Agreement, dated as of April 15, 2019, by and between Recro Gainesville LLC and Teva Pharmaceutical... (Filed With SEC on April 18, 2019)

Agreement, dated March 25, 2019, by and among Recro Pharma, Inc., Engine Capital, L.P., Engine Jet Capital, L.P., Engine Investments, LLC, and Arnaud Ajdler (Filed With SEC on March 28, 2019)

Manufacturing and Supply Agreement, dated as of February 8, 2019, by and between Recro Pharma, Inc. and Novartis Pharma AG (Filed With SEC on March 6, 2019)

Second Amendment to Credit Agreement and Investment Documents, dated February 28, 2019, by and among the Recro Pharma, Inc., the guarantors party thereto, the lenders party... (Filed With SEC on March 4, 2019)

Registration Rights Agreement, dated February 19, 2019, by and between Recro Pharma, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 19, 2019)

Amendment to License Agreement, dated October 31, 2018, by and between Cornell University and Recro Pharma, Inc (Filed With SEC on February 19, 2019)

Common Stock Purchase Agreement, dated February 19, 2019, by and between Recro Pharma, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 19, 2019)

First Amendment to Credit Agreement and Investment Documents, dated December 28, 2018, by and among the Recro Pharma, Inc., the guarantors party thereto, the lenders party... (Filed With SEC on January 4, 2019)

First Amendment to Warrant to Purchase Common Stock, dated December 20, 2018 (Filed With SEC on December 28, 2018)

Second Amendment to Purchase and Sale Agreement, dated December 20, 2018, by and between Recro Pharma, Inc., Recro Gainesville LLC, Alkermes Pharma Ireland Limited, Daravita... (Filed With SEC on December 28, 2018)

Second Amendment to Asset Transfer and License Agreement, dated December 20, 2018, by and between Recro Gainesville LLC and Alkermes Pharma Ireland Limited (Filed With SEC on December 28, 2018)

Recro Pharma, Inc. 2018 Amended and Restated Equity Incentive Plan (Filed With SEC on May 9, 2018)

Registration Rights Agreement, dated March 2, 2018, by and between Recro Pharma, Inc. and Aspire Capital Fund, LLC (Filed With SEC on March 2, 2018)

Form of Award Agreement for Restricted Stock Unit Inducement Awards (Filed With SEC on March 2, 2018)

Common Stock Purchase Agreement, dated March 2, 2018, by and between Recro Pharma, Inc. and Aspire Capital Fund, LLC (Filed With SEC on March 2, 2018)

Sales Agreement, dated as of December 29, 2017, by and between Recro Pharma, Inc. and Cowen and Company, LLC (Filed With SEC on December 29, 2017)

Common Stock Purchase Warrant, dated November 17, 2017, in favor of Athyrium Opportunities III Acquisition LP (Filed With SEC on November 20, 2017)

Common Stock Purchase Warrant, dated November 17, 2017, in favor of Athyrium Opportunities II Acquisition LP (Filed With SEC on November 20, 2017)

Credit Agreement, dated as of November 17, 2017, by and between Recro Pharma, Inc. and Athyrium Opportunities III Acquisition LP (Filed With SEC on November 20, 2017)

Security Agreement, dated as of November 17, 2017, by Recro Pharma, Inc. in favor of Athyrium Opportunities III Acquisition LP (Filed With SEC on November 20, 2017)

Employment Agreement, dated August 21, 2017, between Recro Pharma, Inc. and Jyrki Mattila, MD, PhD, MBA (Filed With SEC on November 9, 2017)

Third Amendment to the Development, Manufacturing and Supply Agreement, dated June 15, 2017, by and between Alkermes Pharma Ireland Limited and Recro Pharma, Inc (Filed With SEC on August 11, 2017)

Licensing Agreement, dated June 30, 2017, by and between Cornell University and Recro Pharma, Inc (Filed With SEC on August 11, 2017)

Master Manufacturing Services Agreement, dated July 14, 2017, by and between Patheon UK Limited and Recro Ireland Limited (Filed With SEC on August 11, 2017)

Product Agreement, dated July 14, 2017, by and between Patheon UK Limited and Recro Ireland Limited (Filed With SEC on August 11, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on June 9, 2017)

SECOND AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on March 9, 2017)

THIRD AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on March 9, 2017)

FOURTH AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on March 9, 2017)

SIXTH AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on March 9, 2017)

SEVENTH AMENDMENT TO CREDIT AGREEMENT AND FIRST AMENDMENT TO PLEDGE AND SECURITY AGREEMENT (Filed With SEC on March 9, 2017)

First Amendment to Development, Manufacturing and Supply Agreement (Filed With SEC on March 9, 2017)

Second Amendment to Development, Manufacturing and Supply Agreement (Filed With SEC on March 9, 2017)

FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT (Filed With SEC on December 8, 2016)

[ ] Shares Recro Pharma, Inc. Common Stock PURCHASEAGREEMENT (Filed With SEC on December 1, 2016)

1,986,666 Shares RecroPharma, Inc. Common Stock PURCHASE AGREEMENT (Filed With SEC on August 17, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on July 5, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on March 24, 2016)

AMENDMENT TO ASSET TRANSFER AND LICENSE AGREEMENT (Filed With SEC on December 23, 2015)

Award Agreement for Restricted Stock Units under the Recro Pharma, Inc. Amended and Restated Equity Incentive Plan (Filed With SEC on December 22, 2015)

FIFTH AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on November 13, 2015)

DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT BETWEEN ALKERMES PHARMA IRELAND LIMITED AND RECRO PHARMA, INC. (Filed With SEC on August 14, 2015)

Date: 26 June2003 ELAN CORPORATION, PLC. AND WATSON LABORATORIES, INC. AMENDED AND RESTATED LICENCEAND SUPPLY AGREEMENT (VERAPAMIL) (Filed With SEC on August 14, 2015)

SUPPLEMENTAL AGREEMENT (Filed With SEC on August 14, 2015)

SUPPLEMENTAL AGREEMENT NO. 2 TO THE AMENDED AND RESTATEDLICENSE AND SUPPLY AGREEMENT (GENERIC VERAPAMIL) (Filed With SEC on August 14, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 8, 2015)

RECRO PHARMA, INC. AMENDED AND RESTATED EQUITY INCENTIVE PLAN (Filed With SEC on June 26, 2015)

EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEENFILED SEPARATELY WITH THE SECURITIES AND... (Filed With SEC on May 12, 2015)

FIRST AMENDMENT TO CREDIT AGREEMENT (Filed With SEC on April 16, 2015)

RECRO PHARMA, INC. 2013 EQUITY INCENTIVE PLAN AWARD AGREEMENT FOR [ ] (Filed With SEC on March 25, 2015)

PURCHASE AND SALE AGREEMENT byand among ALKERMES PHARMA IRELAND LIMITED, DARAVITA LIMITED, EAGLE HOLDINGSUSA, INC., RECRO PHARMA, INC. and RECRO PHARMA LLC Dated as of March 7,... (Filed With SEC on March 11, 2015)

WARRANT TO PURCHASE STOCK (Filed With SEC on March 11, 2015)

FORM OF WARRANT (Filed With SEC on March 11, 2015)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on February 3, 2015)

COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on February 3, 2015)

AMENDMENT NO. 1 TO THEEMPLOYMENT AGREEMENT Between Recro Pharma, Inc. and [ ] (Filed With SEC on December 19, 2014)

RECRO PHARMA, INC. 2013 EQUITY INCENTIVE PLAN (Filed With SEC on March 13, 2014)

RECRO PHARMA, INC. 2013 EQUITY INCENTIVE PLAN AWARD AGREEMENT FOR (Filed With SEC on March 13, 2014)

RECRO PHARMA, INC. UNDERWRITING AGREEMENT (Filed With SEC on February 11, 2014)

INVESTOR RIGHTS AGREEMENT (Filed With SEC on November 29, 2013)

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on November 29, 2013)

EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND... (Filed With SEC on November 29, 2013)

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on November 29, 2013)

EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND... (Filed With SEC on November 29, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on November 29, 2013)

RECRO PHARMA, INC. 2008 STOCK OPTION PLAN (Filed With SEC on November 29, 2013)

RECRO PHARMA, INC. 2008 STOCK OPTION PLAN AWARD AGREEMENT FOR [employees name] (Filed With SEC on November 29, 2013)

RECRO PHARMA, INC. 2013 EQUITY INCENTIVE PLAN (Filed With SEC on November 29, 2013)

RECRO PHARMA, INC. 2013 EQUITY INCENTIVE PLAN AWARD AGREEMENT FOR (Filed With SEC on November 29, 2013)

MASTER CONSULTING SERVICES AGREEMENT (Filed With SEC on November 29, 2013)

OFFICE SERVICES AGREEMENT (Filed With SEC on November 29, 2013)

Amendment #1 to Office Services Agreement (Filed With SEC on November 29, 2013)

Recro Pharma, Inc. Summary of Compensation Arrangement for the Board of Directors for Non-Employee Directors (Filed With SEC on November 29, 2013)

Category

Industry

Companies

Contracts

Recro Pharma, Inc. Contracts & Agreements